The spectrum of nonalcoholic fatty liver disease (NAFLD) includes steatosis, nonalcoholic
steatohepatitis (NASH), and cirrhosis. Recognition and timely diagnosis of these different
stages, particularly NASH, is important for both potential reversibility and limitation of
complications. Liver biopsy remains the clinical standard for definitive diagnosis. Diagnostic
tools minimizing the need for invasive procedures or that add information to histologic data
are important in novel management strategies for the growing epidemic of NAFLD. We …